TP53 and rectal cancer: Therefore, we performed drug combination experiments in seven rectal cancer organoid lines (five of them previously tested, two new lines as unbiased set, all of them RAS mutated, four TP53 wild type, and three TP53 mutated) using high-resolution drug concentration matrices.